Search alternatives:
values decrease » values increased (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ct values » _ values (Expand Search), i values (Expand Search)
a larger » a large (Expand Search), _ larger (Expand Search), _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
Showing 121 - 140 results of 1,782 for search '(( ct values decrease ) OR ((( c large decrease ) OR ( a larger decrease ))))', query time: 0.63s Refine Results
  1. 121
    Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif

    Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
    Save to List
    Saved in:
  2. 122
    Image 8_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif

    Image 8_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…”
    Save to List
    Saved in:
  3. 123
    Source data for Fig 4C.

    Source data for Fig 4C. by Isabel Raposo (21615517)

    Published 2025
    Save to List
    Saved in:
  4. 124
    Source data for Fig 1C.

    Source data for Fig 1C. by Isabel Raposo (21615517)

    Published 2025
    Save to List
    Saved in:
  5. 125
    (A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)).

    (A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 c... by Shakeel Ahmad Khan (13202394)

    Published 2025
    Save to List
    Saved in:
  6. 126
    Growth kinetics of YFV-17D/Asibi chimeras in C6/36 cells.

    Growth kinetics of YFV-17D/Asibi chimeras in C6/36 cells. by Anja vom Hemdt (19787189)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 127
    A. Quality of evidence: TOTVA vs. COT. B. Quality of evidence: TOTVA vs. NTET (including robotic approaches).

    A. Quality of evidence: TOTVA vs. COT. B. Quality of evidence: TOTVA vs. NTET (including robotic approaches). by Huixia Ren (500186)

    Published 2025
    Save to List
    Saved in:
  8. 128
    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage.

    Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. by Verónica M. Negrón-Pérez (20691412)

    Published 2025
    Save to List
    Saved in:
  9. 129
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 130
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 131
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 132
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 133
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 134
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”
    Save to List
    Saved in:
  15. 135
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  16. 136
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  17. 137
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 138
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  19. 139
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 140
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: